HOME > IN THE NEWS

In The News

Science Daily

February 6, 2024

Initial trial suggests invariant natural killer cell therapy improves survival

CGTlive

January 16, 2023

AgenT-797 (MiNK Therapeutics), an allogeneic off-the-shelf invariant natural killer T-cell therapy was well-tolerated and improved survival inpatients with COVID-19-associated acute respiratory distress syndrome (ARDS) in addition to mechanical ventilation or ECMO.

CGTlive

November 18, 2022

The allogeneic off-the-shelf invariant natural killer T-cell (iNKT) therapy, agenT-797 (MiNK Therapeutics), was well-tolerated and improved survival in patients with COVID-19-associated acute respiratory distress syndrome (ARDS) in addition to mechanical ventilation or ECMO.

7 News

November 14, 2022

MiNK Therapeutics, based in Lexington, believes its new cell therapy program could eventually replace chemotherapy with a less invasive treatment.

CBS

November 10, 2022

BOSTON –A Massachusetts company is working on new technology that it says could make chemotherapy a thing of the past.

EndPoint News

August 22, 2022

The massive tailwinds that fed the sails of hundreds of biotechs during the first 18 months of the Covid-19 pandemic ended up stalling around the beginning of 2022, causing dozens of public and private drug developers alike to enact layoffs, prune their pipelines, shutter and search for alternatives.

LifeScience Leader

August 1, 2023

Many people would say they know what a diverse company is. Many could recite all the ways a company might encourage or increase diversity in its ranks. Many would recognize a diverse company if they saw one. But few people actually work in one.

CGTlive

June 21, 2022

CGTLive spoke with Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, to learn more about the advantages of iNKT cells and the company’s CARDIS platform. She discussed data seen so far with AgenT-797.